Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...

"Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump" was originally created and published by ...

Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago. The COVID-19 vaccine ...

Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...

Moderna has received marketing authorisation from the European Commission for its updated COVID-19 vaccine, Spikevax, which ...

The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...

Spikevax has the same formulation as the Moderna COVID-19 vaccine that was authorized for emergency use (EUA) by the U.S. Food and Drug Administration (FDA) on Dec. 18, 2020, according to the FDA ...

TV Helicopter Crew Appears to Spoil NFL Team’s Name Reveal (Video) You can watch the whole monologue at the top of the page. The fake ad for Spikevax kicks in around 6 minutes, 40 seconds in.

If Your Time is short • Spikevax and Comirnaty are brand names for the Moderna and Pfizer COVID-19 vaccines, respectively. The drug formulation is the same for the branded and non-branded vaccines.